DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
MORRISTOWN, N.J., Feb. 24, 2016 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that it will release its fourth quarter and full-year 2015 financial results on Thursday, March 10, 2016, before the market opens. Doug Drysdale, Chairman and Chief Executive Officer, and Sanjay Patel, Chief Financial Officer, will host a conference call to discuss the results, as follows.
| Date: | Thursday, March 10 | |||
| Time: | 8:30 AM EST | |||
| Toll free (U.S.): | 888-572-7025 | |||
| International: | 719-325-2432 | |||
| Webcast (live and replay): | http://public.viavid.com/index.php?id=118501 |
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company targets underserved therapeutic areas such as CNS, including neurology and psychiatry, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its Pernix sales force, uses contracted sales organizations to market its non-core, cough and cold products, and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
Investor Relations Sanjay Patel, (800) 793-2145 ext. 1009 Chief Financial Officer [email protected] Matthew P. Duffy, 212.915.0685 LifeSci Advisors, LLC [email protected]
